Quinoline–hydrazone hybrids as dual mutant EGFR inhibitors with promising metallic nanoparticle loading: rationalized design, synthesis, biological investigation and computational studies-Reference-Cited by-同舟云学术

Quinoline–hydrazone hybrids as dual mutant EGFR inhibitors with promising metallic nanoparticle loading: rationalized design, synthesis, biological investigation and computational studies

Published:2022 Issue:38 Volume:46 Page:18207-18232
ISSN:1144-0546
Container-title:New Journal of Chemistry
language:en
Short-container-title:New J. Chem.

Author:

Elrayess Ranza¹^ORCID,Darwish Khaled M.²^ORCID,Nafie Mohamed S.³^ORCID,El-Sayyed Gharieb S.⁴⁵^ORCID,Said Mohamed M.¹,Yassen Asmaa S. A.¹^ORCID

Affiliation:

1. Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt

2. Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt

3. Chemistry Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt

4. Microbiology and Immunology Department, Faculty of Pharmacy, Galala University, New Galala City, Suez, Egypt

5. Drug Radiation Research Department, National Centre for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt

Abstract

A novel quinoline–hydrazone hybrid induced apoptosis in MCF-7 cells through dual mutant EGFR inhibition with promising metallic nanoparticle loading.

Publisher

Royal Society of Chemistry (RSC)

Subject

Materials Chemistry,General Chemistry,Catalysis

Link

http://pubs.rsc.org/en/content/articlepdf/2022/NJ/D2NJ02962F

Reference114 articles.

1. Breast cancer statistics, 2019

2. Recent Progress in the Development of Anticancer Agents

3. Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019)